Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 18/20 | 0.41 |
| ▸ | CPB1 | P15086 | 5/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15925039 | 0.84 | SCN9A (0.39) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL15592491 | 0.79 | CYP2C9 (0.42) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL24004547 | 0.79 | CPB2 (0.47) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL16508840 | 0.79 | CYP2C9 (0.44) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL15601885 | 0.79 | CYP2C9 (0.44) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL52215 | 0.78 | CYP2C9 (0.47) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL163222 | 0.78 | CYP2C9 (0.47) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL52216 | 0.78 | CYP2C9 (0.47) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| SCHEMBL16508860 | 0.76 | CPB2 (0.51) | CPB2CPB1CYP2C9TSHRCYP2C19 | |
| Hydrochloric Acid SCHEMBL3843450 | 0.76 | TDP1 (0.49) | CPB2CPB1CYP2C9TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796256-B2 | Substituted thiazolidinedione indazoles, indoles and benzotriazoles as estrogen-related receptor-α modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-05 | — | — | US | disclosed |
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294780-A1 | SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-a MODULATORS | ESR2, IGF1R, ESRRA | CPB2 3671/4885CPB1 4403/4885CYP2C9 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.